Femcon Fe Patent Expiration

Femcon Fe is a drug owned by Allergan Pharmaceuticals International Ltd. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 06, 2019. Details of Femcon Fe's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6667050 Chewable oral contraceptive
Apr, 2019

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Femcon Fe's patents.

Given below is the list of recent legal activities going on the following patents of Femcon Fe.

Activity Date Patent Number
Patent litigations
File Marked Found 20 Jan, 2016 US6667050 (Litigated)
File Marked Found 17 Dec, 2015 US6667050 (Litigated)
Change in Power of Attorney (May Include Associate POA) 30 Apr, 2010 US6667050 (Litigated)
Correspondence Address Change 29 Apr, 2010 US6667050 (Litigated)
Patent Issue Date Used in PTA Calculation 23 Dec, 2003 US6667050 (Litigated)
Recordation of Patent Grant Mailed 23 Dec, 2003 US6667050 (Litigated)
Issue Notification Mailed 04 Dec, 2003 US6667050 (Litigated)
Receipt into Pubs 14 Nov, 2003 US6667050 (Litigated)
Application Is Considered Ready for Issue 13 Nov, 2003 US6667050 (Litigated)
Receipt into Pubs 07 Oct, 2003 US6667050 (Litigated)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Femcon Fe is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Femcon Fe's family patents as well as insights into ongoing legal events on those patents.

Femcon Fe's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Femcon Fe's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 06, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Femcon Fe Generics:

Ethinyl Estradiol; Norethindrone is the generic name for the brand Femcon Fe. 16 different companies have already filed for the generic of Femcon Fe, with Barr having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Femcon Fe's generic

Alternative Brands for Femcon Fe

Femcon Fe which is used for contraception., has several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Apil
Taytulla

(uses Ethinyl Estradiol; Norethindrone)

Used for contraception.
Lo Minastrin Fe

(uses Ethinyl Estradiol; Norethindrone)

Used for preventing pregnancy.
Minastrin 24 Fe

(uses Ethinyl Estradiol; Norethindrone)

Used for contraception.
Bayer Hlthcare
Yaz Used for contraception, prevention of pregnancy, and treating premenstrual dysphoric disorder in premenopausal females.
Beyaz Used for contraception, prevention of pregnancy, and treating mood changes and anxiety in women with PMDD who choose oral contraceptives.
Yasmin Used for contraception.
Natazia Used for preventing pregnancy and treating heavy menstrual bleeding in women who use oral contraceptives.
Safyral Used for preventing pregnancy and raising folate levels to reduce the risk of neural tube defects in pregnancy.
Evofem Inc
Phexxi used for contraception.
Organon
Implanon Used for contraception.
Nexplanon Used for contraception.
Teva Branded Pharm
Quartette Used for contraception.
Seasonale Used for contraception in women.
Seasonique Used for preventing pregnancy in women using oral contraceptives.
Loseasonique Used for contraceptive purposes.
Loestrin 24 Fe

(uses Ethinyl Estradiol; Norethindrone)

Used for preventing pregnancy.
Wyeth Pharms Inc
Lybrel Used for contraception.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone. Given below is the list of those drugs and companies owning them.



Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone, Femcon Fe's active ingredient. Check the complete list of approved generic manufacturers for Femcon Fe





About Femcon Fe

Femcon Fe is a drug owned by Allergan Pharmaceuticals International Ltd. It is used for contraception. Femcon Fe uses Ethinyl Estradiol; Norethindrone as an active ingredient. Femcon Fe was launched by Apil in 2003.

Approval Date:

Femcon Fe was approved by FDA for market use on 14 November, 2003.

Active Ingredient:

Femcon Fe uses Ethinyl Estradiol; Norethindrone as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone ingredient

Treatment:

Femcon Fe is used for contraception.

Dosage:

Femcon Fe is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.035MG;0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL